Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int J STD AIDS ; 33(13): 1134-1141, 2022 11.
Article in English | MEDLINE | ID: mdl-36214529

ABSTRACT

BACKGROUND: We describe 11 cases of refractory vulvovaginal yeast infections (RVVYI) treated using oral voriconazole with or without concomitant topical agents. METHODS: Retrospective case-note review of all women prescribed oral voriconazole to treat RVVYI in five Sexual Health Clinics from Jan 2010-March 2020. Demographic details, clinical features, diagnostic results and treatment outcomes were collected. RESULTS: 11 women with vulvovaginal symptoms for a median of 1 year were treated with voriconazole. RVVYI was diagnosed clinically and confirmed on microscopy and culture with speciation. 10/11 isolates were fluconazole resistant, 1 intermediately sensitive, 10/11 were either fully or intermediately sensitive to voriconazole. All had received prior fluconazole and clotrimazole and 10/11 had used at least 2-weeks of one or more second-line antifungals with non-clearance of the yeast. Oral voriconazole 400 mg BD day-1, then 200 mg BD 13-days was prescribed and 10/11 women completed the course. Concomitant topical treatment was used by 6/11. Liver and renal function were monitored at 0, 7, 14 days. One woman stopped voriconazole after 5-days due to perioral tingling. Other transient side-effects were nausea (n = 2), photosensitivity, muscle aches, hair thinning (all n = 1), peripheral visual disturbance (n = 2). 8/11 experienced both symptom reduction and yeast clearance. Two women had an initial partial response but experienced resolution of symptoms following a second course of voriconazole. CONCLUSIONS: Our observational data adds to the limited evidence to support voriconazole treatment for RVVYI. A 2-week course of voriconazole was tolerated and completed by 10/11 women. Eight women, five using concomitant topical agents, achieved mycological cure.


Subject(s)
Candidiasis, Vulvovaginal , Fluconazole , Female , Humans , Voriconazole/therapeutic use , Fluconazole/therapeutic use , Saccharomyces cerevisiae , Retrospective Studies , Antifungal Agents/therapeutic use , Candidiasis, Vulvovaginal/drug therapy , Candidiasis, Vulvovaginal/diagnosis
3.
Int J STD AIDS ; 30(2): 198-200, 2019 02.
Article in English | MEDLINE | ID: mdl-30284955

ABSTRACT

Organ transplant recipients are at a higher risk of pre-malignant human papillomavirus-associated lesions due to immunosuppression. The efficacy of immunomodulants such as imiquimod 5% is not yet fully evaluated in this population. We describe a case of vulval intra-epithelial neoplasia in a renal transplant recipient which was successfully treated with topical imiquimod.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma in Situ/drug therapy , Imiquimod/administration & dosage , Ointments , Tumor Virus Infections/complications , Vulva/pathology , Vulvar Neoplasms/drug therapy , Administration, Topical , Antineoplastic Agents/therapeutic use , Carcinoma in Situ/pathology , Carcinoma in Situ/virology , Female , Humans , Imiquimod/therapeutic use , Immunosuppression Therapy , Kidney/pathology , Kidney Transplantation , Middle Aged , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Transplant Recipients , Treatment Outcome , Vulvar Neoplasms/pathology , Vulvar Neoplasms/virology
5.
J Fam Plann Reprod Health Care ; 42(2): 143-51, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26259896

ABSTRACT

OBJECTIVES: To assess the feasibility and acceptability of screening attendees at a sexual health clinic (SHC) for alcohol misuse, and delivering a brief intervention (BI). To explore the effect of this BI on drinking and sexual behaviour. METHODS: A consecutive sample of consenting SHC attendees aged ≥16 years were screened using Alcohol Use Disorders Identification Test Consumption (AUDIT-C). Men scoring ≥5 and women scoring ≥4 were invited to complete the full AUDIT, alcohol diary and baseline questionnaire. INTERVENTIONS: Participants were randomised to receive BI by a trained sexual health professional or a standard alcohol leaflet (usual care, UC). All were followed up for changes in alcohol and sexual behaviour at 6 weeks and 6 months. A fidelity check and staff focus group were undertaken. RESULTS: Of 664 participants screened, 215 (32%) were eligible for randomisation and 207 were included in the final analysis: 103 (BI) and 104 (UC). Follow-up rates were 54% and 47% at 6 weeks and 6 months, respectively. Both groups reduced alcohol consumption though the degree of change did not differ between them. There was some evidence of positive changes in sexual health risk in both groups. BI was delivered as intended, adding 5 minutes to the consultation, and staff feedback was positive. CONCLUSIONS: Alcohol misuse was common in SHC attendees. Systematic assessment and BI for alcohol misuse was feasible and acceptable to staff and patients. Identification and provision of standard information alone appeared to influence drinking and sexual behaviour. TRIAL REGISTRATION NUMBER: ISRCTN19452424.


Subject(s)
Alcohol Drinking/epidemiology , Alcohol-Related Disorders/diagnosis , Alcohol-Related Disorders/therapy , Patient Acceptance of Health Care/statistics & numerical data , Sexual Behavior/statistics & numerical data , Adult , Age Factors , Ambulatory Care , Ambulatory Care Facilities , Feasibility Studies , Female , Humans , Male , Poverty , Risk-Taking , Sex Factors , Sexual Behavior/psychology , United Kingdom , Urban Population , Young Adult
7.
Acute Med ; 4(3): 108, 2005.
Article in English | MEDLINE | ID: mdl-21655531

ABSTRACT

The chest radiograph is one of the most challenging images to interpret reliably, yet accurate film reading can be very rewarding professionally and can significantly improve patient management. These skills are important for all professionals working in acute medicine and acquiring them requires a comprehensive book collection and a wide experience but above all a good teacher.

SELECTION OF CITATIONS
SEARCH DETAIL
...